Drug Profile


Alternative Names: API-2; NSC 154020; NSC 280594; PTX-200 - Prescient Therapeutics; TCN; TCN-P; Tricirbine phosphate monohydrate; VQD-002; VQD-002-ORAL

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of South Florida
  • Developer Albert Einstein College of Medicine; Cahaba Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; Prescient Therapeutics; VioQuest Pharmaceuticals
  • Class Ribonucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Protein kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Breast cancer; Ovarian cancer
  • No development reported Haematological malignancies; Pancreatic cancer; Solid tumours
  • Discontinued Cancer; HIV infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02930109)
  • 04 Feb 2016 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top